![Illustration of coworkers sitting at table with New York City skyline in background](https://www.organon.com/wp-content/uploads/sites/2/2023/01/MicrosoftTeams-image-37.png?resize=1036,551)
Organon Business Development
Partnering with Organon. We believe in a better and healthier every day for every woman.
![Photo of Daniel Karp, Chief Business Development Officer](https://www.organon.com/wp-content/uploads/sites/2/2021/09/Daniel-Karp.jpg?resize=800,650)
“We’re committed to leadership in women’s health, expanding our biosimilars portfolio, and building upon our global presence. At Organon, we believe in the power of collaboration. Working together, we can achieve far more for patients.”
Daniel Karp, Executive Vice President, Corporate Development
We aspire to be the partner of choice in our areas of focus
![Icon with symbol for female encircling plus sign representing women's health](https://www.organon.com/wp-content/uploads/sites/2/2021/10/Organon_Icon_Color_WomensHealth_small.png?resize=404,268)
Women's health
We are committed to building a pipeline and portfolio of products to address her underserved needs. We seek opportunities in the areas of contraception, fertility, maternal and peripartum, and conditions that are unique to women or impact her differently.
![Icon of two hexagons representing biosimilars](https://www.organon.com/wp-content/uploads/sites/2/2021/08/Organon_Icon_Color_Biosimilars.png?resize=404,268)
Biosimilars
Our goal is to become the world class, global commercial partner of choice to biosimilar manufacturers and to expand our portfolio in oncology, immunology and beyond. We seek opportunities to collaborate with partners on programs that are expected to launch at or close to the loss of exclusivity of the reference product.
![Icon of packaged products on conveyor belt representing established medicines](https://www.organon.com/wp-content/uploads/sites/2/2021/08/Organon_Icon_Color_Commercialization.png?resize=404,268)
Established brands
Organon has a global footprint and broad portfolio of over 50 established brands, including products in cardiovascular, respiratory, dermatology and non-opioid pain management. We seek collaborations that add products and are synergistic with our infrastructure and capabilities.
Key business development contacts
![Daniel Karp](https://www.organon.com/wp-content/uploads/sites/2/2024/03/Daniel-Karp-gallery.jpg?resize=292,194)
Daniel Karp
Executive Vice President, Corporate Development
![Carol Ferguson](https://www.organon.com/wp-content/uploads/sites/2/2024/03/Carol-Ferguson-gallery.jpg?resize=292,194)
Carol Ferguson
Women’s Health Business Development
![Troy Silfies](https://www.organon.com/wp-content/uploads/sites/2/2024/03/Troy-Silfies-gallery.jpg?resize=292,194)
Troy Silfies
Biosimilars Business Development
![Alla Marinyansky](https://www.organon.com/wp-content/uploads/sites/2/2024/03/Alla-Marinyansky-gallery.jpg?resize=292,194)
Alla Marinyansky
Established Brands & Regional Business Development
![Elizaveta Zakharova](https://www.organon.com/wp-content/uploads/sites/2/2024/03/Elizaveta-Zakharova-gallery.png?resize=292,194)
Elizaveta Zakharova
Europe and Canada Business Development
![Joshua Cooper](https://www.organon.com/wp-content/uploads/sites/2/2024/03/Joshua-Cooper-gallery.jpg?resize=292,194)
Joshua Cooper
Asia Pacific Japan Business Development
![Victor Matsuy](https://www.organon.com/wp-content/uploads/sites/2/2024/03/Victor-Matsuy-gallery.jpg?resize=292,194)
Victor Matsuy
Latin America, Middle East, and Africa Business Development
![Abby Zhou](https://www.organon.com/wp-content/uploads/sites/2/2024/03/Abby-Zhou-gallery.jpg?resize=292,194)
Abby Zhou
China Business Development
![Neil Boyle](https://www.organon.com/wp-content/uploads/sites/2/2024/03/Neil-Boyle-gallery.jpg?resize=292,194)
Neil Boyle
Alliance Management & Integration
![Jaquelina Lee](https://www.organon.com/wp-content/uploads/sites/2/2024/03/Jaquelina-Lee-gallery.jpg?resize=292,194)
Jaquelina Lee
Business Development Operations
To reach out for any other purpose, please visit the contact us page.